Advances in polymer-based nanocomposites have revolutionized biomedical applications
over the last two decades. Heparin (HP), being a highly bioactive polymer of biological …

Breast cancer is the most common female cancer globally, with approximately 12% of
patients eventually developing metastatic disease. Critically, limited effective treatment …

The burden of venous thromboembolism (VTE) is high in patients with cancer, particularly
those with metastatic disease and those receiving chemotherapy. The use of heparin and …

Low molecular weight heparins (LMWHs) are produced by chemical or enzymatic
depolymerization of unfractionated heparin (UFH). Besides their well-known anticoagulant …

Bemiparin is a low molecular weight heparin (LMWH) indicated for the acute treatment of
deep vein thrombosis with or without pulmonary embolism, for the prophylaxis of venous …

Introduction The haemostatic system plays an important role in the process of cancer
development and spread. Anticoagulants, mainly low molecular weight heparins, could …

Low molecular weight heparins (LMWHs) are currently used as an anticoagulant agent
since unfractionated heparin (UFH) can cause serious adverse drug reactions. LMWHs are …

Low molecular weight heparin is a Heparin derivative, produced from commercial-grade
Heparin through Chemical or enzymatic depolymerization. LMWH has remained a favored …

Venous thromboembolism (VTE) and cancer are strongly associated, and present a major
challenge in cancer patient treatment. Cancer patients have a higher risk of developing VTE …

Heparin, one of the common anticoagulants, is clinically used to prevent and treat venous
thromboembolism (VTE). Though it has been the drug of choice for many advanced medical …